198 related articles for article (PubMed ID: 9762359)
21. Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination.
Rofstad EK; Gaustad JV; Egeland TA; Mathiesen B; Galappathi K
Int J Cancer; 2010 Oct; 127(7):1535-46. PubMed ID: 20091868
[TBL] [Abstract][Full Text] [Related]
22. Transformation of the microvascular system during multistage tumorigenesis.
Ryschich E; Schmidt J; Hämmerling GJ; Klar E; Ganss R
Int J Cancer; 2002 Feb; 97(6):719-25. PubMed ID: 11857345
[TBL] [Abstract][Full Text] [Related]
23. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
Rak J; Yu JL
Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
[TBL] [Abstract][Full Text] [Related]
24. Cancer vascularization: implications in radiotherapy?
Koukourakis MI; Giatromanolaki A; Sivridis E; Fezoulidis I
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):545-53. PubMed ID: 10974475
[TBL] [Abstract][Full Text] [Related]
25. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy.
Siemann DW; Warrington KH; Horsman MR
Radiother Oncol; 2000 Oct; 57(1):5-12. PubMed ID: 11033183
[TBL] [Abstract][Full Text] [Related]
26. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
27. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy.
Rak JW; St Croix BD; Kerbel RS
Anticancer Drugs; 1995 Feb; 6(1):3-18. PubMed ID: 7538829
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
Eberhard A; Kahlert S; Goede V; Hemmerlein B; Plate KH; Augustin HG
Cancer Res; 2000 Mar; 60(5):1388-93. PubMed ID: 10728704
[TBL] [Abstract][Full Text] [Related]
29. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.
Ralph SJ; Rodríguez-Enríquez S; Neuzil J; Saavedra E; Moreno-Sánchez R
Mol Aspects Med; 2010 Apr; 31(2):145-70. PubMed ID: 20206201
[TBL] [Abstract][Full Text] [Related]
30. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy targeting to tumor endothelium.
Bazan-Peregrino M; Seymour LW; Harris AL
Cancer Gene Ther; 2007 Feb; 14(2):117-27. PubMed ID: 17096029
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors.
Tsuzuki Y; Fukumura D; Oosthuyse B; Koike C; Carmeliet P; Jain RK
Cancer Res; 2000 Nov; 60(22):6248-52. PubMed ID: 11103778
[TBL] [Abstract][Full Text] [Related]
33. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P
J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567
[TBL] [Abstract][Full Text] [Related]
34. Morphologic instability and cancer invasion.
Cristini V; Frieboes HB; Gatenby R; Caserta S; Ferrari M; Sinek J
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6772-9. PubMed ID: 16203763
[TBL] [Abstract][Full Text] [Related]
35. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
[TBL] [Abstract][Full Text] [Related]
36. Endothelial precursor cell-based therapy to target the pathologic angiogenesis and compensate tumor hypoxia.
Collet G; Szade K; Nowak W; Klimkiewicz K; El Hafny-Rahbi B; Szczepanek K; Sugiyama D; Weglarczyk K; Foucault-Collet A; Guichard A; Mazan A; Nadim M; Fasani F; Lamerant-Fayel N; Grillon C; Petoud S; Beloeil JC; Jozkowicz A; Dulak J; Kieda C
Cancer Lett; 2016 Jan; 370(2):345-57. PubMed ID: 26577811
[TBL] [Abstract][Full Text] [Related]
37. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML
J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306
[TBL] [Abstract][Full Text] [Related]
39. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
Erber R; Thurnher A; Katsen AD; Groth G; Kerger H; Hammes HP; Menger MD; Ullrich A; Vajkoczy P
FASEB J; 2004 Feb; 18(2):338-40. PubMed ID: 14657001
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia: a key regulator of angiogenesis in cancer.
Liao D; Johnson RS
Cancer Metastasis Rev; 2007 Jun; 26(2):281-90. PubMed ID: 17603752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
